checkAd

     117  0 Kommentare ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix - Seite 4

    For further information, please contact:

    Media Contact Switzerland and Europe:
    Christophe Lamps
    Dynamics Group
    cla@dynamicsgroup.ch
    +41 22 308 6220 Office
    +41 79 476 26 87 Mobile

    Media Contact U.S.:
    Marion Janic
    RooneyPartners LLC
    mjanic@rooneyco.com
    +1 212 223 4017 Office
    +1 646 537 5649 Mobile

    CEO Office Contact:
    Shauna Dillon
    Shauna.dillon@obseva.ch
    +41 22 552 1550

    Investor Contact:
    Mario Corso
    Senior Director, Investor Relations
    mario.corso@obseva.com
    +1 857 972 9347 Office
    +1 781 366 5726 Mobile

    Lesen Sie auch

    Attachment


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 4 von 4

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix - Seite 4 Phase 3 trial (PRIMROSE 2) met primary and secondary efficacy endpoints93.9% responder rate for 200 mg with ABT (p < 0.001)56.7% responder rate for 100 mg without ABT (p < 0.001)Both doses achieved important clinically relevant secondary endpoints …